ABSTRACT
Tight junctions (TJ) are essential components of polarized epithelia, and E-cadherin is important for their formation and maintenance. The bronchial epithelial cell line, 16HBE14o-expresses E- and P-cadherin, but not N-cadherin. E- and P-cadherin levels changed during culture, the former increasing after confluence, and the latter were markedly reduced. All detectable E-cadherin was bound to beta- and gamma-catenins. We investigated involvement of E-cadherin with epithelial integrity using an E-cadherin specific, function-blocking antibody, SHE78-7. Surprisingly, apical SHE78-7 exposure caused a prompt fall in transepithelial resistance (TER), while TER remained unchanged for 8 hrs after basal exposure then dropped. SHE78-7 exposure increased epithelial permeability to mannitol, inulin, and 9.5 kDa and 77 kDa dextrans and caused fragmentation and loss of the tight junction protein, ZO-1, from the cell borders in some areas. Ultrastructural studies showed that all junctional intercellular contact was lost in the center of SHE78-7 induced lesions. Near the lesion periphery, epithelial structure was maintained, but TJs were dysfunctional as shown by ruthenium red penetration. Analysis of epithelial penetration by SHE78-7 revealed discrete, local defects in the apical barrier at the top of some cell hills that permitted rapid access of the antibody to E-cadherin near the apical surface. In contrast, after basal exposure, antibody initially engaged with E-cadherin nearer the basal surface and only accessed apical E-cadherin later. Taken together with the TER measurements, these data suggest compartmentalization of E-cadherin function within 16HBE14o-cells, with only the apical E-cadherin adjacent to the tight junctions contributing to the function of the latter.
Subject(s)
Bronchi/cytology , Cadherins/metabolism , Epithelial Cells/metabolism , Animals , Blotting, Western , Cell Line , Cytoskeletal Proteins , Dextrans/metabolism , Dose-Response Relationship, Drug , Epithelium/metabolism , Humans , Immunoglobulin G/metabolism , Immunohistochemistry , Inulin/metabolism , Mannitol/metabolism , Membrane Proteins/metabolism , Mice , Occludin , Phosphoproteins/metabolism , Protein Binding , Rats , Ruthenium Red/pharmacology , Tight Junctions , Time Factors , Zonula Occludens-1 ProteinABSTRACT
Inhalation of pharmacologically active substances for medicinal, social, or recreational purposes has been prevalent for centuries but experience of exploiting the lung as a route of delivery for treatment of nonrespiratory diseases is limited. Despite the success of current applications such as anesthetics, the utility of the lung for drug delivery is not well appreciated, despite advantages such as rapid onset of action. Two drawbacks are the relatively poor efficiency of current inhalation devices, especially for large molecules, and the poor patient acceptability of inhalers. Advances now being made in pulmonary delivery technology may provide the impetus needed for the development of new inhaled presentations of drugs such as peptide hormones and other biologically derived molecules. Molecules of various sizes can be delivered in clinically relevant quantities via the lung. In vitro methods show that lipophilic drugs are absorbed through the alveolar membrane more quickly. Early work in animal models has already shown that absorption of analgesic and antiinflammatory drugs that are not well absorbed orally can be improved by delivering them by inhalation. This work may soon give rise to new formulations for therapeutic use.
Subject(s)
Drug Delivery Systems , Lung/metabolism , Administration, Inhalation , Animals , Biological Availability , Drug Therapy/trends , Humans , Nebulizers and Vaporizers , Particle SizeABSTRACT
Epithelial intercellular adhesion is fundamental to the formation of the airway epithelial protective barrier. In this respect, cadherins are important because these adhesion molecules regulate formation and maintenance of epithelial intercellular junctions. To study the importance of airway epithelial integrity in determining susceptibility to virus infection, we used a replication-incompetent adenovirus, RAd35, and an E-cadherin specific function-blocking antibody, SHE78-7, to disrupt intercellular contacts in human bronchial epithelial cell line 16HBE14o- and primary bronchial epithelial cells. After exposure of 16HBE14o- cell cultures to SHE78-7, disruption of the transepithelial permeability barrier was indicated by a loss of transepithelial electrical resistance and an associated increase of mannitol, inulin, and dextran paracellular flux. Subsequent exposure of SHE78-7-treated cell cultures to RAd35 showed a remarkable increase in adenoviral infection as assessed by beta-galactosidase reporter gene expression. In cultures exposed to SHE78-7, disruption of E-cadherin function resulted in infection equivalent to that in control cultures using 16-fold lower viral titers. These studies show that manipulation of E-cadherin function provides a specific means of altering epithelial integrity that in turn determines resistance of airway epithelia to adenoviral infection.
Subject(s)
Adenoviridae Infections/pathology , Adenoviridae Infections/physiopathology , Adenoviruses, Human , Cadherins/physiology , Epithelial Cells/virology , Intercellular Junctions/virology , Cell Communication/physiology , Cell Line , Epithelial Cells/pathology , Epithelial Cells/physiology , Humans , Intercellular Junctions/physiologyABSTRACT
Fibrosis in the reticular layer beneath the epithelial basement membrane is a feature of airway remodeling in human asthma. We previously reported the presence of subepithelial fibrosis (SEF) in a disease model of atopic asthma in which mice were sensitized and intratracheally challenged with ovalbumin (OVA) (Blyth and colleagues, Am. J. Respir. Cell Mol. Biol. 1996;14:425-438). Here, we describe further studies to quantify the degree of SEF after its induction by repeated exposure of the airways to allergen. The amount of subepithelial reticulin in the airways of animals challenged three times with 80 microg OVA was typically increased 1. 4-fold. The increased amount of reticulin showed no reduction after a 50-d period after the third allergen challenge. A reduction in SEF was achieved by daily treatment with dexamethasone (DEX) for 8 d during the allergen challenge period, or by treatment with anti-interleukin-5 antibody (TRFK5) at the time of allergen challenge. Postchallenge treatment with DEX for 15 d resulted in significant resolution of previously established SEF. Severe nonallergic inflammation during repeated exposure of airways to lipopolysaccharide did not induce SEF. The results indicate that development of SEF is associated with eosinophil infiltration into airways, and may occur only when the inflammatory stimulus is allergic in nature.
Subject(s)
Asthma/prevention & control , Epithelial Cells/drug effects , Pulmonary Fibrosis/prevention & control , Allergens/immunology , Animals , Anti-Inflammatory Agents/pharmacology , Antibodies/pharmacology , Asthma/immunology , Asthma/pathology , Dexamethasone/pharmacology , Disease Models, Animal , Eosinophils/drug effects , Eosinophils/pathology , Epithelial Cells/pathology , Inflammation/immunology , Inflammation/pathology , Inflammation/prevention & control , Interleukin-5/immunology , Lung/drug effects , Lung/metabolism , Lung/pathology , Male , Mice , Mice, Inbred BALB C , Ovalbumin/immunology , Pulmonary Fibrosis/immunology , Pulmonary Fibrosis/pathology , Reticulin/drug effects , Reticulin/metabolismABSTRACT
A series of N6,2-disubstituted adenosine analogues have been synthesized and their functional activity measured against A2a and A1 receptors. Examples of compounds with both a lipophilic N6-substituent and amino-functionalized 2-position were highly active at the A2a receptor on the human neutrophil.
Subject(s)
Adenosine/chemistry , Adenosine/pharmacology , Purinergic P1 Receptor Agonists , Adenosine/analogs & derivatives , Anti-Inflammatory Agents/chemistry , GTP-Binding Proteins , Solubility , Structure-Activity RelationshipABSTRACT
Mast cells play a potentially important role in fibroproliferative diseases, releasing mediators including tryptase that are capable of stimulating fibroblast proliferation and procollagen synthesis. The mechanism by which tryptase stimulates fibroblast proliferation is unclear, although recent studies suggest it can activate protease-activated receptor (PAR)-2. We therefore investigated the role of PAR-2 in tryptase-induced proliferation of human fetal lung and adult lung parenchymal and airway fibroblasts and, for comparative purposes, adult dermal fibroblasts. Tryptase (0.7-70 mU/ml) induced concentration-dependent increases in proliferation of all fibroblasts studied. Antipain, bis(5-amidino-2-benzimidazolyl)methane, and benzamidine inhibited tryptase-induced fibroblast proliferation, demonstrating that proteolytic activity is required for the proliferative effects of tryptase. RT-PCR demonstrated the presence of PAR-2 mRNA, and immunohistochemical staining localized PAR-2 to the cell surface of lung fibroblasts. In addition, specific PAR-2 activating peptides, SLIGKV and SLIGRL, mimicked the proliferative effects of tryptase. In contrast, human dermal fibroblasts only weakly stained with the PAR-2 antibody, PAR-2 mRNA was almost undetectable, and fibroblasts did not respond to PAR-2 activating peptides. These results suggest that tryptase induces lung, but not dermal, fibroblast proliferation via activation of PAR-2 and are consistent with the hypothesis that the release of tryptase from activated mast cells may play an important role in the fibroproliferative response observed in asthma, chronic obstructive pulmonary disease, and patients with pulmonary fibrosis.
Subject(s)
Fibroblasts/cytology , Lung/cytology , Mast Cells/enzymology , Receptors, Thrombin/physiology , Serine Endopeptidases/physiology , Adult , Animals , Cell Division/drug effects , Cell Division/physiology , Cells, Cultured , Chymases , Fetus , Humans , Immunohistochemistry , Lung/embryology , Peptide Fragments/pharmacology , RNA, Messenger/metabolism , Rats , Receptor, PAR-2 , Receptors, Thrombin/genetics , Reverse Transcriptase Polymerase Chain Reaction , Serine Endopeptidases/pharmacology , Serine Proteinase Inhibitors/pharmacology , Trypsin/pharmacology , TryptasesABSTRACT
OBJECTIVE AND DESIGN: The aim was to determine the time courses for the changes in airway function, airway reactivity, influx of inflammatory cells and levels of the pro-inflammatory cytokines, interleukin (IL)-5 and IL-8 in bronchoalveolar lavage fluid (BALF), and the plasma levels of cortisol and ACTH after antigen challenge to determine whether a temporal link could be established between these events. METHODS: Airway function was measured as specific airway conductance (sGsw) in conscious ovalbumin (OvA)-sensitized guinea pigs using whole body plethysmography at intervals after an inhalation challenge with ovalbumin (0.5% for 10 min). Airway responses to the inhaled spasmogen, U46619 (30 ng/ml, 60 s), were measured at 3, 6 and 24 h after challenge. In separate animals, bronchoalveolar lavage fluid (BALF) was obtained after anaesthetic overdose either before challenge or at 1, 3, 6, 12, or 24 h after OvA challenge. Total and differential cell counts of eosinophils and neutrophils were performed on BALF and levels of IL-5 and IL-8 determined by scintillation proximity assays and ELISA, respectively. Plasma cortisol and ACTH levels were determined by RIA kits in blood removed by cardiac puncture at intervals after challenge. RESULTS: An early phase bronchoconstriction occurred which resolved by 3 h and was followed by a late phase between 17 and 24 h. Airway hyperresponsiveness to inhaled U46619, was evident at 3, 6 and 24 h after antigen challenge. Increased IL-5[BALF] was observed by 60 min post challenge implicating a performed storage site. In contrast, IL-8[BALF] was not raised until 3 h post challenge. There was a significant infiltration of neutrophils and eosinophils by 3 and 6 h, respectively. IL-5[BALF] further increased up to 24 h, during the appearance of the late phase of bronchoconstriction and whilst eosinophilia was maximal. Plasma cortisol levels were increased 1 and 3 hours after antigen challenge, thereafter returning to baseline levels. CONCLUSIONS: The hyperresponsiveness appears to be dissociated from the appearance of eosinophils in lavage fluid. The early appearance of IL-5, however, could be a trigger for the migration of eosinophils and development of hyper-responsiveness. The increased plasma cortisol levels occurring after antigen challenge were presumably due to the stress involved and these would be expected to exert an endogenous anti-inflammatory effect.
Subject(s)
Bronchial Hyperreactivity/metabolism , Bronchial Hyperreactivity/pathology , Cytokines/metabolism , Hydrocortisone/blood , Leukocytes/pathology , Lung/metabolism , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Adrenocorticotropic Hormone/blood , Airway Resistance , Animals , Bronchial Hyperreactivity/immunology , Bronchial Hyperreactivity/physiopathology , Bronchoalveolar Lavage Fluid/cytology , Bronchoconstriction/drug effects , Guinea Pigs , In Vitro Techniques , Interleukin-5/metabolism , Interleukin-8/metabolism , Leukocytes/metabolism , Lung/pathology , Male , Ovalbumin/toxicity , Plethysmography, Whole Body , Time FactorsABSTRACT
We recently described a murine model of atopic asthma in which a marked, extensive hyperplasia of airway goblet cells is induced by repeated challenge of ovalbumin (OA)-sensitized mice with intratracheally administered allergen (Am. J. Respir. Cell Mol. Biol. 1996;14:425-438). We report here the time course of the duration of this feature and of its spontaneous resolution in the absence of further allergen exposure. Induction of severe neutrophilic inflammation in the airways by repeated intratracheal administration of lipopolysaccharide failed to induce goblet cell hyperplasia (GCH) to as great a degree as that induced by allergen, suggesting that nonallergic inflammation is a relatively poor inducer of this phenotype change in mice. When a "subclinical" infection of the lungs with the human A2 strain of respiratory syncytial virus was superimposed on the model of atopic asthma, recruitment of monocytes and lymphocytes to the airways was enhanced and a discharge of goblet cell mucin contents was observed. This may partly explain the respiratory difficulty that typifies virally induced exacerbations of asthma in humans. Daily systemic treatment of sensitized mice with dexamethasone during the period of allergen challenge produced a dose-related suppression of developing GCH, while similar treatment during the period following the establishment of extensive hyperplasia induced an accelerated resolution toward a normal epithelial phenotype. These results confirm and extend the relevance of this model as a representation of the human disease.
Subject(s)
Asthma/pathology , Dexamethasone/therapeutic use , Lung/pathology , Respiratory Syncytial Virus Infections/complications , Respiratory Tract Infections/complications , Allergens , Animals , Anti-Inflammatory Agents/therapeutic use , Asthma/complications , Asthma/drug therapy , Bronchoalveolar Lavage Fluid/cytology , Eosinophils , Epithelial Cells/pathology , Hyperplasia , Leukocyte Count , Lipopolysaccharides/pharmacology , Lymphocytes , Macrophages , Male , Mice , Mice, Inbred BALB C , Neutrophils , Ovalbumin/immunologyABSTRACT
Eosinophils are believed to play an important part in the pathogenesis of equine diseases such as helminth infestation and the allergic skin disease, sweet itch. It has been shown that adherence of human eosinophils to the connective tissue matrix protein fibronectin enhances cell activation and survival time. If adherence causes similar changes in the properties of equine eosinophils, cell-induced tissue damage at a site of parasitic infestation or allergic response would be exacerbated. However, investigation of this hypothesis requires identification of mediators that cause equine eosinophil adherence. Since the equivalent recombinant equine proteins were not available, the present study reports the effects of recombinant human (rh) C5a and IL-5 on the adherence of equine peripheral blood eosinophils (EPBEs) to fibronectin in vitro. The effects of LTB4 and PAF on EPBE adherence to fibronectin were also examined and phorbol myristate acetate (PMA) was used as a positive control. PMA caused a dose-related increase in EPBE adherence to fibronectin-coated plastic. In comparison, rh C5a produced a much smaller response which was only evident at the highest dose tested. On the other hand, rhIL-5 induced a small, but significant dose-related increase in EPBE adherence. Moreover, this response was in part dependent on the beta 1 integrin Very Late Antigen-4 (VLA4). Since adherence to serum-coated plastic was also increased by IL-5, beta 2 integrins may be activated and/or up-regulated on EPBEs by the cytokine. Neither LTB4 nor PAF caused EPBE adherence to fibronectin but prior incubation with these mediators increased the response of cells to IL-5. There were no differences between the responses of EPBEs isolated from horses with clinical signs of sweet itch and normal animals. Thus, whilst up-regulation of IL-5-induced adherence may occur locally in tissues in vivo, it does not appear to take place in the circulation. Finally, C5a, PAF and LTB4, but not IL-5, caused equine neutrophil adherence to fibronectin demonstrating the different responses of granulocytes to these mediators. The results obtained in the present study have shown that mediators which may be released at sites of inflammatory or allergic reactions can induce or enhance eosinophil adherence to tissue matrix protein. Thus, these mediators can now be used in future studies to determine if cell adherence may alter eosinophil activation or survival time.
Subject(s)
Eosinophils/immunology , Horses/immunology , Animals , Cell Adhesion/drug effects , Cell Adhesion/physiology , Complement C5a/pharmacology , Eosinophils/drug effects , Eosinophils/physiology , Female , Fibronectins/metabolism , Horse Diseases/etiology , Humans , In Vitro Techniques , Interleukin-5/pharmacology , Leukotriene B4/pharmacology , Neutrophils/immunology , Neutrophils/physiology , Platelet Activating Factor/pharmacologyABSTRACT
This article describes the development and validation of a scintillation proximity assay (SPA) sensitive for guinea-pig interleukin-5 (IL-5). SPA beads were coated with TRFK-5, a monoclonal antibody directed against mouse IL-5, which is known also to bind guinea-pig IL-5. The assay is a simple competitive binding assay between [125I]-rh-IL-5 and the IL-5, in a sample of guinea-pig bronchoalveolar lavage fluid (BALF), for the binding site on the TRFK-5-coated beads. IL-5 levels in BALF ([IL-5]BALF) were shown to increase in guinea-pigs sensitized to ovalbumin (OvA) and challenged with an OvA inhalation. This occurred at a time (24 h) after challenge when there was also a marked eosinophilia. The assay was validated by treating guinea-pigs with a second antibody, Genzyme 2374-01, directed against IL-5. Treatment with this antibody resulted in a significant reduction of the antigen-induced eosinophilia and concentration of [IL-5]BALF. This observation confirms that the IL-5 identified in BALF also cross-reacts with the antibody Genzyme 2374-01. Interestingly, plasma from sensitized, but unchallenged, guinea-pigs also contained detectable levels of IL-5, and the stimulation of plasma protein extravasation (PPE) within the airways with inhaled histamine also induced a rise in [IL-5]BALF. These observations suggest that the plasma may be an additional source of the IL-5 present in the airways of antigen-challenged guinea-pigs.
Subject(s)
Bronchoalveolar Lavage Fluid/chemistry , Interleukin-5/analysis , Administration, Inhalation , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antibody Formation , Binding, Competitive , Blood Proteins/metabolism , Bronchoalveolar Lavage Fluid/cytology , Eosinophilia/chemically induced , Eosinophilia/drug therapy , Guinea Pigs , Histamine/administration & dosage , Histamine/immunology , Histamine/toxicity , Interleukin-5/immunology , Interleukin-5/metabolism , Male , Mice , Microspheres , Ovalbumin/administration & dosage , Ovalbumin/immunology , Ovalbumin/toxicity , Rats , Recombinant Proteins/analysis , Recombinant Proteins/metabolism , Scintillation CountingABSTRACT
Ovalbumin (OvA) inhalation by sensitized guinea-pigs caused a pronounced rise in interleukin (IL)-5 in bronchoalveolar lavage (BAL) fluid at both 3 and 24 h after antigen exposure. The increased levels at 24 h were attenuated by the phosphodiesterase inhibitors Ro 20-1724 and aminophylline and by dexamethasone, all of which also attenuated the concurrent lung eosinophilia. The rise in IL-5 at 3 h was additionally attenuated by the PDE3 inhibitor, siguazodan, which failed to attenuate the eosinophilia at 24 h. These results suggest a pivotal action of these compounds on the later rise in IL-5. Ro 20-1724, aminophylline, siguazodan and dexamethasone attenuated a rise in IL-8 levels in BAL fluid at 3 h and the subsequent neutrophilia at 24 h. There was no increase in plasma ACTH at 3 and 24 h after OvA challenge but cortisol levels were elevated at 3 h. This was inhibited by Ro 20-1724, siguazodan and dexamethasone. Thus, elevation of plasma cortisol does not explain the anti-inflammatory actions of these compounds. Aminophylline, however, did raise plasma cortisol at both 3 and 24 h after antigen challenge which may be an important further mechanism of action for this compound.
Subject(s)
Adrenocorticotropic Hormone/blood , Bronchial Hyperreactivity/metabolism , Hydrocortisone/blood , Interleukin-5/metabolism , Interleukin-8/metabolism , Lung/drug effects , Phosphodiesterase Inhibitors/pharmacology , 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone/pharmacology , Aminophylline/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Dexamethasone/pharmacology , Eosinophils , Glucocorticoids/pharmacology , Guanidines/pharmacology , Guinea Pigs , Lung/metabolism , Macrophages , Male , Neutrophils , Pyridazines/pharmacologyABSTRACT
We have previously suggested (Trevethick et al., Gut 34, 156-160) that indomethacin-induced ulceration of the rat gastric antrum may be a neutrophil-dependent process. Accordingly, in this study we have used an anti-neutrophil serum (ANS) to investigate the effects of neutrophil depletion on this pathology. In animals pretreated with the ANS to induce a nearly total neutropaenia, indomethacin-induced increases in blood neutrophilia and cell infiltration into the gastric antrum (assessed as LTB4 release ex vivo) were eliminated. In marked contrast, however, ANS pretreatment affected neither the area of mucosa damaged nor the microscopic characteristics or distribution of the lesions. These results suggest that, in contrast to the published reports examining indomethacin-induced ulceration of the gastric fundus, neutrophil infiltration is not involved in the pathogenesis of indomethacin-induced ulceration of the rat gastric antrum.
Subject(s)
Indomethacin/toxicity , Neutrophils/physiology , Pyloric Antrum/drug effects , Stomach Ulcer/chemically induced , Animals , Female , Neutrophils/drug effects , Pyloric Antrum/pathology , Radioimmunoassay , Rats , Rats, Sprague-Dawley , Stomach Ulcer/pathology , Stomach Ulcer/physiopathologyABSTRACT
Airways mucociliary clearance (MCC), which continuously removes inhaled particles and cellular debris from the lungs is impaired in a number of diseases such as bronchitis, asthma and cystic fibrosis. Regulation of MCC under normal conditions is not well understood and the cause of its impairment is ill defined. Animal models have been used to study the regulatory mechanisms of both mucus secretion and MCC and to ascertain the involvement of neural pathways. Cholinergic stimulation is a most effective means of enhancing MCC in molluscs, frogs and mammals including man. Recent data from mammals suggest that MCC is also regulated by neuropeptides either directly (substance P) or by facilitating the stimulatory effect of cholinergic agents. A better understand of basic regulatory mechanisms of MCC is vital to an understanding of its impairment in respiratory diseases.
Subject(s)
Mucociliary Clearance , Animals , Biological Transport , Histological Techniques/instrumentation , Humans , Mucociliary Clearance/physiology , Neuropeptides/physiology , Parasympathetic Nervous System/physiology , Trachea/metabolismABSTRACT
Intraperitoneal injections of recombinant human granulocyte-macrophage colony stimulating factor (rh-GMCSF, 50 micrograms/kg-1 daily) or interleukin-3 (rh-IL3, 50 micrograms kg-1 daily) for two days, induced an increase in the percentage of bone marrow and pulmonary airway eosinophils in the guinea-pig. In addition, rh-IL3-treated animals exhibited an increase (21%) in blood neutrophils. Exposure of guinea-pigs to an aerosol of platelet activating factor (PAF) gives rise to a selective pulmonary eosinophil accumulation, maximal at 48 h. The eosinophilic response to PAF was significantly enhanced in rh-GMCSF-treated guinea-pigs but was suppressed in rh-IL3-treated animals.
Subject(s)
Colony-Stimulating Factors/pharmacology , Eosinophils/drug effects , Growth Substances/pharmacology , Interleukin-3/pharmacology , Platelet Activating Factor/pharmacology , Aerosols , Animals , Bronchoalveolar Lavage Fluid/cytology , Granulocyte-Macrophage Colony-Stimulating Factor , Guinea Pigs , In Vitro Techniques , Platelet Activating Factor/administration & dosage , Recombinant Proteins/pharmacologyABSTRACT
1. Intravenous infusion of (+/-) isoprenaline (1-100 micrograms kg-1 h-1) enhanced airway responses (resistance, RL; and compliance, Cdyn) to histamine (1.0-1.8 micrograms kg-1) and bombesin (100-240 ng kg-1), whereas airway responses to vagal stimulation remained unchanged. 2. Bilateral vagotomy before intravenous infusion of (+/-)isoprenaline (100 micrograms kg-1 h-1) prevented development of airway hyperreactivity to histamine or bombesin, yet vagotomy after infusion of isoprenaline was without effect. 3. Prior treatment with atropine (1 mg kg-1) did not influence the capacity of (+/-)isoprenaline (100 micrograms kg-1 h-1) to increase airway reactivity to bombesin. 4. Despite a 500-fold difference in spasmolytic potency in vivo, infusion of (+)isoprenaline (100 micrograms kg-1 h-1) or (-)isoprenaline (100 micrograms kg-1 h-1) increased reactivity of the airways to histamine or bombesin to a comparable extent. 5. Neither adrenaline (100 micrograms kg-1 h-1) nor forskolin (600 micrograms kg-1 h-1) increased reactivity of the airways to histamine or bombesin. 6. Intravenous infusion of dopamine (100 micrograms kg-1 h-1) or noradrenaline (100 micrograms kg-1 h-1) increased reactivity of the airways to histamine or bombesin. 7. Intravenous infusion of (+/-) propranolol (100 micrograms kg-1 h-1) increased reactivity of the airways to histamine or bombesin which was partially inhibited by bilateral vagal section. 8. Depletion of circulating platelets by lytic anti-platelet serum or concomitant infusion of an antagonist of platelet-activating factor (PAF), ginkgolide B (1 mg kg-1 h-1) did not diminish the capacity of (+/-)isoprenaline (100 micrograms kg-1 h-1) to induce hyperreactivity of the airways to histamine or bombesin. 9. These observations indicate that (+/-)isoprenaline can induce airway hyper-reactivity by a mechanism unrelated to beta-adrenoceptor activation, but which is dependent upon intact vagus nerves.
Subject(s)
Airway Resistance/drug effects , Histamine/pharmacology , Isoproterenol/pharmacology , Animals , Atropine/pharmacology , Blood Platelets/metabolism , Bombesin/pharmacology , Bronchodilator Agents/pharmacology , Colforsin/pharmacology , Dopamine/administration & dosage , Dopamine/pharmacology , Epinephrine/pharmacology , Guinea Pigs , Injections, Intravenous , Isoproterenol/administration & dosage , Male , Norepinephrine/administration & dosage , Norepinephrine/pharmacology , Platelet Activating Factor/antagonists & inhibitors , Propranolol/administration & dosage , Propranolol/pharmacology , Rabbits , Vagotomy , Vagus Nerve/physiologyABSTRACT
1. Guinea-pigs were sensitized with 3 injections of ovalbumin (OA) (1 or 10 micrograms per animal) using Al(OH)3 and pertussis vaccine as adjuvants at two week intervals. 2. Sensitized guinea-pigs were challenged with an aerosol of OA (0.1%) over a one hour period and both airway reactivity and cellular content of bronchoalveolar lavage (BAL) fluid were assessed at intervals for up to 7 days. 3. Guinea-pigs sensitized with 1 microgram of ovalbumin responded to an aerosol of OA with increased pulmonary airway eosinophilia, which was evident 1 day after challenge and was present for up to 7 days. Airway hyperreactivity was not detectable in these animals. 4. Guinea-pigs sensitized with 10 micrograms of ovalbumin responded to an aerosol of OA with increased pulmonary airway neutrophilia and eosinophilia and with increased airway reactivity which was maximal between 8 and 24 h after exposure to OA. 5. Depletion of circulating platelets or neutrophils, by use of selective antisera, did not alter either the magnitude of eosinophilia or the intensity of airway reactivity in sensitized guinea-pigs (10 micrograms) exposed to an aerosol of OA. 6. Pretreatment of sensitized guinea-pigs (10 micrograms) for 6 days with AH 21-132, aminophylline, dexamethasone or ketotifen inhibited pulmonary airway eosinophilia, but did not diminish airway hyperreactivity. Neither eosinophil accumulation nor development of airway hyperreactivity was influenced by treatment with mepyramine or salbutamol over a 6 day period before OA inhalation. 7. Although eosinophilia may occur in association with increased airway reactivity in this animal model, there is no evidence of a causal relationship.
Subject(s)
Asthma/drug therapy , Eosinophils/immunology , Lung/immunology , Respiratory Hypersensitivity/immunology , Animals , Asthma/physiopathology , Blood Platelets/drug effects , Bronchoalveolar Lavage Fluid/pathology , Dinoprost/pharmacology , Guinea Pigs , Histamine/pharmacology , In Vitro Techniques , Male , Neutrophils/drug effects , Ovalbumin/immunology , Passive Cutaneous Anaphylaxis/drug effects , Pertussis Vaccine/immunology , Rabbits , Respiratory Hypersensitivity/physiopathologyABSTRACT
Inhalation of ovalbumin by conscious, sensitized guinea pigs induced two phases of airway obstruction measured at 2 h (EAR) and at 17 h (LAR), respectively. In addition to causing airway obstruction, allergen challenge induced an accumulation in the bronchial lumen of eosinophil and neutrophil polymorphonuclear leukocytes at 17 h. Intraperitoneal injection of guinea pigs with a specific rabbit anti-guinea pig neutrophil serum 24 h before challenge reduced the number of circulating neutrophils by 94% and the airway neutrophilia after challenge by 90%, but it had no effect on the magnitude of either the EAR or the LAR. The observation that the LAR was not effected by neutropenia supports previous conclusions derived from experiments using the anti-allergic drugs, cromolyn sodium and nedocromil sodium, and the beta 2-adrenoceptor stimulant, albuterol, that, although there is a temporal relationship between neutrophil accumulation in the airways and the peak of the LAR, this polymorphonuclear leukocyte does not play a central role in the pathophysiologic processes that give rise to the late-phase response to guinea pig airways.
Subject(s)
Hypersensitivity, Delayed/immunology , Neutrophils/physiology , Ovalbumin , Respiratory Hypersensitivity/immunology , Administration, Inhalation , Airway Resistance , Animals , Blood Component Removal/methods , Bronchial Provocation Tests , Bronchoalveolar Lavage Fluid/immunology , Bronchoalveolar Lavage Fluid/pathology , Eosinophils , Guinea Pigs , Hypersensitivity, Delayed/pathology , Hypersensitivity, Delayed/physiopathology , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/pathology , Hypersensitivity, Immediate/physiopathology , Immunization , Leukocyte Count , Male , Ovalbumin/administration & dosage , Respiratory Hypersensitivity/pathology , Respiratory Hypersensitivity/physiopathologyABSTRACT
1. Exposure of guinea-pigs to aerosols of platelet activating factor (PAF) (0.01 to 100 micrograms ml-1) induced a dose-dependent increased incidence of eosinophils in bronchoalveolar lavage fluid (BAL) at 48 h. Total leucocyte numbers and the percentages of lymphocytes and neutrophils were unchanged in BAL fluid. 2. Increased numbers of eosinophils were detected in BAL 1 h after exposure to PAF but eosinophilia was not maximal until 48 h. One week after exposure to PAF, the percentage of eosinophils in BAL was within the normal range. 3. Depletion of circulating platelets or neutrophils by intravenous injection of specific antisera did not modify accumulation of eosinophils in the airway lumen following inhalation of PAF (10 micrograms ml-1). 4. PAF-induced pulmonary airway eosinophil accumulation was inhibited by treatment with SDZ 64-412, a selective PAF-antagonist, whether the compound was administered before, or 30 min after, inhalation of PAF. 5. Pulmonary airway eosinophil accumulation due to inhaled PAF (10 micrograms ml-1) was inhibited by prior treatment with aminophylline, cromoglycate, ketotifen, dexamethasone and AH 21-132. 6. Pulmonary airway eosinophil accumulation due to inhaled PAF (10 micrograms ml-1) was not inhibited by prior treatment with indomethacin, salbutamol or mepyramine.
Subject(s)
Asthma/drug therapy , Eosinophils/drug effects , Lung/cytology , Platelet Activating Factor/pharmacology , Aerosols , Animals , Asthma/pathology , Blood Platelets/immunology , Bronchi/cytology , Bronchi/drug effects , Eosinophils/cytology , Guinea Pigs , In Vitro Techniques , Lung/drug effects , Male , Neutrophils/drug effects , Platelet Activating Factor/administration & dosage , Time FactorsABSTRACT
Beta-adrenoceptor agonists are potent and selective relaxants of airway smooth muscle. They produce symptomatic bronchodilatory effects and are the most widely used therapy in asthma. In patients with asthma, they usually effect a reduction of airway resistance, but there have been several reports of episodes of increased airway obstruction, arterial hypoxaemia and even death associated with such therapy. "Anomalous or paradoxical bronchospasm" are appropriate terminologies to describe this unexpected phenomenon. Five mechanisms have been proposed to account for anomalous responses to these substances: 1) reactive myogenic tone; 2) metabolic products with spasmogenic activity; 3) adrenoceptor tachyphylaxis; 4) increased inflammatory burden; and 5) induction of airway hyperreactivity. Following a review of the relative merits of each proposal, it is concluded that increased inflammatory burden and induction of airway hyperreactivity, alone or in combination, provide the most plausible explanation for paradoxical bronchospasm.